Neurodegeneration-associated proteins and inflammation in sporadic inclusion-body myositis

Advances in Experimental Medicine and Biology

Volumn 487, Issue , 2001, Pages 219-228

  Lampe, J B ^a   Walter, M C ^a   Reichmann, H ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; CONFERENCE PAPER; INCLUSION BODY MYOSITIS; INFLAMMATION; MUSCLE WEAKNESS; NERVE DEGENERATION; PATHOGENESIS; PRION DISEASE; PRIORITY JOURNAL;

EID: 0034990675     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-1249-3_18     Document Type: Conference Paper

References (71)

1. Does overexpression of betaAPP in aging muscle have a pathogenic role and a relevance to Alzheimer's disease? Clues from inclusion body myositis, cultured human muscle, and transgenic mice
2. Update on the use of intravenous immune globulin in the treatment of patients with inflammatory muscle disease
3. Dysphagia as a frequent manifestation in patients with inclusion body myositis
4. Inclusion body myositis
5. Polymyositis, dermatomyositis and inclusion-body myositis
6. Inclusion body myositis: New concepts
7. Immune-mediated conditions and antibodies associated with sporadic inclusion body myositis
8. Sporadic inclusion-body myositis and its similarities to Alzheimer disease brain. Recent approaches to diagnosis and pathogenesis, and relation to aging
9. Strong immunoreactivity of alpha 1-antichymotrypsin co-localizes with beta-amyloid protein and ubiquitin in vacuolated muscle fibers of inclusion-body myositis
10. Prion protein is abnormally accumulated in inclusion-body myositis
11. Apolipoprotein E alleles as risk factors in Alzheimer's disease
12. Genes contributing to Alzheimer's disease
13. Apolipoprotein E epsilon 4 in inclusion body myositis
14. Prion gene and apolipoprotein E in sporadic inclusion-body myositis
15. Apolipoprotein E type epsilon 4 allele frequency is not increased in patients with sporadic inclusion-body myositis
16. Fatal familial insomnia and familial Creutzfeldt-Jakob disease: Disease phenotype determined by a DNA polymorphism
17. Molecular genetics of prion diseases in France
18. Similar genetic susceptibility in iatrogenic and sporadic Creutzfeldt-Jakob disease
19. Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease
20. Polymorphisms of the prion protein gene in Italian patients with Creutzfeldt-Jakob disease
21. Polymorphism at codon 129 of the prion protein gene determines cerebellar pathology in Creutzfeldt-Jakob disease
22. The same prion strain causes vCJD and BSE
23. Methionine homozygosity at prion gene codon 129 may predispose to sporadic inclusion-body myositis
24. Prion gene genetics and sporadic inclusion-body myositis
25. Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments
26. Prion diseases
27. Linkage ofa prion protein missense variant to Gerstmann-Straussler syndrome
28. Familial neurological disease associated with spongiform encephalopathy
29. Degeneration of the cerebellar and hypothalamo-neurohypophysial systems in sheep with scrapie; and its relationship to human system degenerations
30. Myopthy in sheep. Its relationship to scrapie and to dermatomyositis and muscular dystrophy
31. The skeletal muscle of sheep affected with scrapie
32. Etiology and pathogenesis of prion diseases
33. Global surveillance, diagnosis and therapy of human transmissible spongiform encephalopathies
34. Abnormal accumulation of prion protein mRNA in muscle fibers of patients with sporadic inclusion-body myositis and hereditary inclusion- body myopathy
35. Prion protein is strongly immunolocalized at the postsynaptic domain of human normal neuromuscular junctions
36. Degeneration of skeletal muscle, peripheral nerves, and the central nervous system in transgenic mice overexpressing wild-type prion proteins
37. Hereditary inclusion body myopathy maps to chromosome 9pl-ql
38. Dominant hereditary inclusion-body myopathy gene (IBM3) maps to chromosome region 17p13.1
39. Inclusion body myositis
40. Inclusion body myositis and myopathies
41. Cellular mechanisms in inflammatory myopathies
42. Oligoclonal expansion of muscle infiltrating T cells in inclusion body myositis
43. Coculture with autologous myotubes of cytotoxic T cells isolated from muscle in inflammatory myopathies
44. Immunogenetics of inflammatory myopathies
45. HLA associations with inclusion body myositis
46. HLA allele distribution distinguishes sporadic inclusion body myositis from hereditary inclusion body myopathies
47. Clinical, serologic, and immunogenetic features of familial idiopathic inflammatory myopathy
48. Local T-cell proliferation and differentiation in inflammatory myopathies
49. Mapping of a candidate region for susceptibility to inclusion body myositis in the human major histocompatibility complex
50. Histocompatibility antigens in sporadic inclusion-body myositis
51. Limited T-cell receptor V gene usage in inclusion body myositis
52. Inclusion body myositis: A distinct variety of idiopathic inflammatory myopathy
53. Inclusion body myositis: A chronic persistent mumps myositis?
54. Inclusion body myositis: Investigation of the mumps virus hypothesis by polymerase chain reaction
55. Inclusion body myositis: The mumps virus hypothesis
56. Inclusion body myositis in HIV-1 and HTLV-1 infected patients
57. Inclusion body myositis: Atypical clinical presentations
58. Inclusion body myositis in post-poliomyelitis muscular atrophy
59. Infectious amyloidosis: Subacute spongiform encphalopathies as transmissible cerebral amyloidosis
60. A kinetic model for amyloid formation in the prion diseases: Importance of seeding
61. Chaperoning brain diseases
62. AlphaB-crystallin immunolocalization yields new insights into inclusion body myositis
63. Inclusion body myositis, muscle blood vessel and cardiac amyloidosis, and transthyretin Val122Ile allele
64. Beta APP gene transfer into cultured human muscle induces inclusion- body myositis aspects
65. Amyloid-beta deposition in skeletal muscle of transgenic mice: Possible model of inclusion body myopathy
66. Transgenic mice over-expressing the C-99 fragment of betaPP with an alpha-secretase site mutation develop a myopathy similar to human inclusion body myositis
67. Increase of nitric oxide synthases and nitrotyrosine in inclusion-body myositis
68. Sporadic inclusion-body myositis and hereditary inclusion-body myopathies: Diseases of oxidative stress and aging?
69. Nitric oxide-induced oxidative stress in autosomal recessive and dominant inclusion-body myopathies
70. Mitochondrial abnormalities and peripheral neuropathy in inflammatory myopathy, especially inclusion body myositis
71. Light and electron microscopic localization of beta-amyloid protein in muscle biopsies of patients with inclusion-body myositis